GDMT — The Four Pillars of HFrEF Therapy
Get All Four on Board. Get to Target.
GDMT — The Four Pillars of HFrEF Therapy
Get All Four on Board. Get to Target.
Definition: HFrEF = symptomatic heart failure with LVEF ≤40%. Four drug classes independently reduce mortality. All four are Class I recommendations. Initiate simultaneously — there is no required sequence.
Part 1 — The Four Pillars at a Glance
| Pillar | Preferred Agents | Start Dose | Target Dose | Key Monitoring / Cautions |
|---|---|---|---|---|
| Pillar 1 ARNI (preferred) Class I, LOE B-R |
Sacubitril/valsartan | 24/26 mg BID | 97/103 mg BID | Stop ACEi 36h before starting. Monitor BP, K+, creatinine. Do not use with ACEi. |
| Pillar 1 Alt ACEi / ARB Class I, LOE A |
Lisinopril, enalapril Candesartan, valsartan |
Lisinopril 2.5–5 mg daily | Lisinopril 20–40 mg daily | ACEi preferred over ARB. ARB if ACEi cough or angioedema. |
| Pillar 2 Beta-Blocker Class I, LOE A |
Carvedilol Metoprolol succinate Bisoprolol |
Carvedilol 3.125 mg BID Metoprolol succ 12.5–25 mg daily Bisoprolol 1.25 mg daily |
Carvedilol 25–50 mg BID Metoprolol succ 200 mg daily Bisoprolol 10 mg daily |
Only these 3 agents proven in HFrEF. Do not substitute atenolol or metoprolol tartrate. Do not start during active decompensation. |
| Pillar 3 MRA Class I, LOE A |
Spironolactone Eplerenone |
Spironolactone 12.5–25 mg daily Eplerenone 25 mg daily |
Spironolactone 25–50 mg daily Eplerenone 50 mg daily |
Check K+ and creatinine at 1 week, 1 month, 3 months. Hold if K+ ≥5.0, Cr >2.5 mg/dL (men) or 2.0 (women), or eGFR <30. |
| Pillar 4 SGLT2i Class I, LOE A |
Dapagliflozin Empagliflozin |
10 mg daily 10 mg daily |
10 mg daily (no titration) 10 mg daily (no titration) |
Benefit independent of diabetes. Do not use if eGFR <25 (dapagliflozin). Check eGFR before starting. |
ARNI is preferred over ACEi for all patients with NYHA Class II–III HFrEF who can tolerate it. Use ACEi or ARB only when ARNI is not feasible. Never combine ARNI with ACEi — risk of life-threatening angioedema.
Part 2 — Initiation Strategy
| Principle | What to Do |
|---|---|
| Start all four early | Initiate all four classes at low doses simultaneously or within the first 2–3 months of diagnosis. Do not wait to optimize one agent before starting the next. |
| Titrate simultaneously | Double doses every 1–2 weeks (beta-blocker: every 2 weeks) as tolerated. Check BP, K+, and creatinine after each uptitration. |
| Creatinine rise is expected | A creatinine rise ≤30% after RAAS inhibitor initiation does not require dose reduction. It is hemodynamic — not nephrotoxicity. Only discontinue for K+ >5.5 mEq/L, Cr rising above threshold, or severe symptomatic hypotension. |
| Reassess LVEF at 3–6 months | After reaching target doses of all four pillars, repeat TTE. If LVEF remains ≤35%, refer for ICD ± CRT evaluation. |
Eplerenone is preferred over spironolactone in post-MI HFrEF (EPHESUS trial) and in men at risk for gynecomastia. Spironolactone is the standard choice in all other HFrEF patients.
Part 3 — What Not to Use
| Drug / Class | Reason to Avoid in HFrEF |
|---|---|
| Non-dihydropyridine CCBs (diltiazem, verapamil) | Class III Harm — negative inotropic effect worsens LV function. Use amlodipine or felodipine if a CCB is needed. |
| Thiazolidinediones (pioglitazone, rosiglitazone) | Class III Harm — increase sodium and water retention; raise HF hospitalization risk. |
| NSAIDs (including COX-2 inhibitors) | Impair diuretic efficacy, cause sodium retention, worsen renal function with RAAS inhibition. Avoid in all HFrEF. |
| Non-approved beta-blockers (atenolol, metoprolol tartrate) | No mortality benefit data in HFrEF. Only carvedilol, metoprolol succinate, and bisoprolol are guideline-approved. |
| ARNI + ACEi simultaneously | Life-threatening angioedema. Must stop ACEi and wait ≥36 hours before starting sacubitril/valsartan. |
Clinical Rule
All four GDMT drugs independently reduce mortality. A patient on one drug is not “on GDMT” — they are on one pillar. The goal is all four at target doses. Initiate early; do not wait to optimize one before starting the next.
This is one of 13 free reference sheets from the APP Cardiology Academy — no account required.